Regulatory & PolicyRecent Congressional scrutiny on Eli Lilly, Pfizer, Merck, BMS, and AbbVie’s clinical research in China highlights an unresolved rift between U.S. government officials and the biopharmaceutical industry. This divide centers on whether China’s biotech expansion threatens national security or offers vital economic value, as transpacific collaborations shape the future of global drug development.
Daniel Cho·Jul 2, 2026
Biotech InnovationIn a landmark event for biotechnology and patient care, the FDA has greenlit Orca Bio’s T-cell therapy, offering hope for those confronting blood cancers and the complex complications of stem cell transplants. This approval not only underscores the progress of cell therapies but also highlights the challenges and opportunities ahead for the field.
Daniel Cho·Jul 1, 2026 
Regulatory & PolicyIn a significant move, the FDA has rejected filings from Unicycive Therapeutics and Sobi due to shortcomings found within their contract manufacturing partners. This decision highlights the ongoing challenges and regulatory scrutiny that biopharma companies face around outsourced production, especially as the demand for novel therapies in chronic disease areas continues to rise.
Daniel Cho·Jul 1, 2026 
Regulatory & PolicyThe detection of Marburg virus cases in western Uganda introduces new complexities for Ebola response teams and regional public health authorities. As central Africa experiences overlapping outbreaks of dangerous viral hemorrhagic fevers, questions about surveillance, containment, resource allocation, and international coordination come to the fore.
Daniel Cho·Jun 30, 2026 
Biotech InnovationIpsen has set the biopharma world abuzz with its $450 million deal to acquire Kartos Therapeutics, aiming to boost its oncology pipeline and deliver a unique, potentially transformative myelofibrosis therapy. The transaction revolves around navtemadlin, an oral small molecule targeting the tumor suppressor protein p53, and highlights the shifting strategic landscape in hematologic cancer drug development.
Daniel Cho·Jun 30, 2026 
Regulatory & PolicyThe Medicare Cost Cap Act, introduced with bipartisan national interest, seeks to set a $5,000 limit on annual out-of-pocket expenses for traditional Medicare beneficiaries. This initiative marks a significant policy movement impacting retirees, care providers, insurers, and the broader healthcare economy.
Daniel Cho·Jun 28, 2026 
AI in Drug DiscoveryAI adoption in medicine has accelerated, but clinicians and researchers warn that generative models fall short in explaining their outputs. Transparent, causally rooted systems could bridge the trust gap and improve care, marking a pivotal inflection point for AI in clinical settings.
Daniel Cho·Jun 27, 2026 
Biopharmaceutical IndustryWith an eye on long-term viability, Moderna is navigating a complex landscape as it transitions from pandemic-era revenues to a diversified portfolio of commercial products. Anticipation is high as Jefferies projects the company will achieve break-even by 2028, pending the success of its R&D initiatives and steady revenue growth.
Daniel Cho·Jun 26, 2026 
Regulatory & PolicyAcross the United States, hundreds of hospitals appear open on paper, but a closer look reveals they have trimmed essential offerings such as emergency care, obstetrics, and psychiatric services. This phenomenon underscores the inadequacy of using closure numbers alone to assess the declining state of healthcare access, especially in rural and underserved areas.
Daniel Cho·Jun 26, 2026 
Biotech InnovationA recent human embryo study highlights breakthroughs in the accuracy of next-generation CRISPR tools, providing insight into early-stage developmental processes. At the same time, these innovations raise profound questions about the responsible application of gene editing and the potential societal consequences of altering the human germline.
Daniel Cho·Jun 26, 2026 
Regulatory & PolicyThe Supreme Court's latest decision on Roundup litigation represents a pivotal legal event with broad implications for both product liability law and public health governance in the United States. This in-depth analysis explores the legal, scientific, and regulatory factors underpinning the Court’s opinion, assessing what it means for consumers, companies, and the courts going forward.
Daniel Cho·Jun 25, 2026 
Medical TechnologyIn a notable move for the medical imaging sector, the FDA recently granted breakthrough designation to two devices leveraging generative AI. These devices are designed to interpret chest X-rays and automate report generation, highlighting the growing importance and clinical acceptance of artificial intelligence in radiology workflows. This development has the potential to redefine both efficiency and accuracy in imaging departments across the United States.
Daniel Cho·Jun 25, 2026 